A 52-week randomised, double-blind, parallel group, placebo controlled, multicenter clinical trial to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once-daily by inhalation, in the maintenance treatment of patients with moderate to severe stable chronic obstructive pulmonary disease